Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00257608 · ClinicalTrials.gov registry record · Phase 3
A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS)
A Phase 3 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,145
- Enrollment target
NCT00257608: Completed Phase 3 study, sponsored by Genentech.
NCT00257608 is a Phase 3 study that has completed, run by Genentech. The registered enrollment target is 1,145 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (48% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00257608, a Phase 3 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,145 participants
- Enrollment target
Study Summary
This is a Phase IIIb, multicenter, randomized, placebo-controlled trial to evaluate the safety and efficacy of chemotherapy+bevacizumab followed by bevacizumab+erlotinib versus bevacizumab+erlotinib placebo in subjects with locally advanced or metastatic NSCLC.
Primary Outcome
PFS was defined as the length of time from randomization until documented disease progression or death from any cause, whichever occurred earlier. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Data presented until cut-off date 18 July 2008.
Interventions
- DRUG placebo
- DRUG bevacizumab
- DRUG erlotinib HCl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,145 participants |
| Start Date | 2006-01 |
| Est. Completion | 2014-11 |
| Phase | Phase 3 |
What the finished NCT00257608 record still lists
NCT00257608 is an interventional study that assigns participants to a tested intervention. Its 1,145 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (48% higher).
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00257608 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00257608 about?
NCT00257608 is a clinical study titled "A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS)". This is a Phase IIIb, multicenter, randomized, placebo-controlled trial to evaluate the safety and efficacy of chemotherapy+bevacizumab followed by bevacizumab+erlotinib versus bevacizumab+erlotinib placebo in subjects with locally advanced or metastatic NSCLC.
What is the current status of trial NCT00257608?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,145 participants. The study started on 2006-01. Estimated completion is 2014-11.
What interventions are being tested in trial NCT00257608?
The interventions under investigation include: placebo (DRUG), bevacizumab (DRUG), erlotinib HCl (DRUG).
Who is sponsoring clinical trial NCT00257608?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00257608's enrollment target sits among peer trials
1,145 242nd of 2000 higher than 1,758 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06129864 · 1,145 participants · Phase 3
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
- NCT06676319 · 1,147 participants · Phase 2
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
- NCT06408181 · 1,150 participants · Phase 3
APPLE: Aspirin to Prevent Pregnancy Loss and Preeclampsia
- NCT06528314 · 1,150 participants · Phase 3
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia